SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
India Ratings & Research, the monitoring agency for Sai Parenterals' IPO, has confirmed NO deviation from the stated use of IPO proceeds. The INR 2,850 million fresh issue (total issue INR 4,087.89 million including OFS) remains fully undeployed, sitting in escrow account with Axis Bank. The IPO conducted March 24-27, 2026 is in early deployment stage. All six stated objects—capacity expansion (INR 1,107.95M), R&D centre (INR 180.23M), debt repayment (INR 143.02M), working capital (INR 330M), subsidiary loan repayment (INR 356.41M), and general corporate purposes (INR 447.40M)—show 'Ongoing' status with projected completion in Fiscal 2027. No unfavorable events affecting project viability were reported.
Positive signal for investors—full IPO proceeds are intact and deployment is proceeding as disclosed in the offer document with no deviations or changes to financing arrangements. The lack of any unfavorable events and ongoing projects aligned to the prospectus supports the company's growth roadmap.